GlassScriptPhysician profile
Grazyna Kedzior
NPI 1457387193
$2,332.95
in general payments reported to CMS, 2019-2025
14 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $443 · 2023: $157 · 2024: $747 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $579.04 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $502.44 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $244.70 | 2024 | Velphoro |
| Ardelyx, INC. | $240.84 | 2024-2025 | Xphozah 30 Mg |
| Chiesi USA, INC. | $208.46 | 2021-2025 | Cleviprex, Kengreal |
| Travere Therapeutics, INC. | $131.28 | 2025 | Filspari |
| Pharmacyclics LLC, An Abbvie Company | $125.01 | 2022 | |
| Lilly USA, LLC | $101.10 | 2021 | |
| Gilead Sciences, INC. | $89.31 | 2024 | Trodelvy |
| Amgen INC. | $46.33 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.90 | 2021 | |
| Shionogi INC | $16.57 | 2025 | Fetroja |
| Pfizer INC. | $15.43 | 2023 | |
| Smith+Nephew, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grazyna Kedzior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.